0492282 - ÚOCHB 2019 RIV GB eng J - Journal Article
Humpolíčková, Jana - Weber, Jan - Starková, Jana - Mašínová, Eva - Günterová, Jana - Flaisigová, Iva - Konvalinka, Jan - Majerová, Taťána
Inhibition of the precursor and mature forms of HIV-1 protease as a tool for drug evaluation.
Scientific Reports. Roč. 8, Jul 11 (2018), č. článku 10438. ISSN 2045-2322. E-ISSN 2045-2322
R&D Projects: GA MŠMT LO1302
Institutional support: RVO:61388963
Keywords : human immunodeficiency virus * type 1 GagPol precursor * conformational ensembles
OECD category: Biochemistry and molecular biology
Impact factor: 4.011, year: 2018
https://www.nature.com/articles/s41598-018-28638-w

HIV-1 protease (PR) is a homodimeric enzyme that is autocatalytically cleaved from the Gag-Pol precursor. Known PR inhibitors bind the mature enzyme several orders of magnitude more strongly than the PR precursor. Inhibition of PR at the precursor level, however, may stop the process at its rate-limiting step before the proteolytic cascade is initiated. Due to its structural heterogeneity, limited solubility and autoprocessing, the PR precursor is difficult to access by classical methods, and limited knowledge regarding precursor inhibition is available. Here, we describe a cell-based assay addressing precursor inhibition. We used a reporter molecule containing the transframe (TFP) and p6* peptides, PR, and N-terminal fragment of reverse transcriptase flanked by the fluorescent proteins mCherry and EGFP on its N- and C-termini, respectively. The level of FRET between EGFP and mCherry indicates the amount of unprocessed reporter, allowing specific monitoring of precursor inhibition. The inhibition can be quantified by flow cytometry. Additionally, two microscopy techniques confirmed that the reporter remains unprocessed within individual cells upon inhibition. We tested darunavir, atazanavir and nelfinavir and their combinations against wild-type PR. Shedding light on an inhibitor's ability to act on non-mature forms of PR may aid novel strategies for next-generation drug design.
Permanent Link: http://hdl.handle.net/11104/0285806